Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem

[1] Lindholm A(1990)The effect of food and bile acid administration on the relative bioavailability of cyclosporine Br J Clin Pharmacol 29 541-549

[2] Henricsson S(1990)High fat meals increase the clearance of cyclosporine Pharmaceut Res 7 46-350

[3] Dahlqvist R(2003)Pharmacogenomics Drug disposition, drug targets and side effect N Engl J Med 348 538-260

[4] Gupta SK(2002)Therapeutic drug monitoring of immunosuppressant drugs in clinical practice Clin Ther 24 330-388

[5] Benet LZ(1997)Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclpsporine Clin Pharmacol Ther 62 248-831

[6] Evans WE(2000)Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method Pharmacogenetics 10 373-112

[7] McLeod HL(2001)Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos J Pharmacol Exp Ther 299 825-192

[8] Kahan BD(2004)Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states Clin Pharmacol Ther 76 104-2524

[9] Keown P(2005)CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population Clin Chim Acta 353 187-698

[10] Levy GA(1996)P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J Clin Invest 97 2517-199

[1] Lindholm A(1990)The effect of food and bile acid administration on the relative bioavailability of cyclosporine Br J Clin Pharmacol 29 541-549

[2] Henricsson S(1990)High fat meals increase the clearance of cyclosporine Pharmaceut Res 7 46-350

[3] Dahlqvist R(2003)Pharmacogenomics Drug disposition, drug targets and side effect N Engl J Med 348 538-260

[4] Gupta SK(2002)Therapeutic drug monitoring of immunosuppressant drugs in clinical practice Clin Ther 24 330-388

[5] Benet LZ(1997)Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclpsporine Clin Pharmacol Ther 62 248-831

[6] Evans WE(2000)Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method Pharmacogenetics 10 373-112

[7] McLeod HL(2001)Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos J Pharmacol Exp Ther 299 825-192

[8] Kahan BD(2004)Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states Clin Pharmacol Ther 76 104-2524

[9] Keown P(2005)CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population Clin Chim Acta 353 187-698

[10] Levy GA(1996)P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J Clin Invest 97 2517-199